Annual Revenue
$2.25 B
+$419.95 M+22.97%
December 31, 2024
Summary
- As of February 22, 2025, ALNY annual revenue is $2.25 billion, with the most recent change of +$419.95 million (+22.97%) on December 31, 2024.
- During the last 3 years, ALNY annual revenue has risen by +$1.40 billion (+166.29%).
- ALNY annual revenue is now at all-time high.
Performance
ALNY Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Revenue
$593.17 M
+$92.25 M+18.42%
December 31, 2024
Summary
- As of February 22, 2025, ALNY quarterly revenue is $593.17 million, with the most recent change of +$92.25 million (+18.42%) on December 31, 2024.
- Over the past year, ALNY quarterly revenue has increased by +$153.45 million (+34.90%).
- ALNY quarterly revenue is now -20.97% below its all-time high of $750.53 million, reached on September 30, 2023.
Performance
ALNY Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
TTM Revenue
$2.25 B
+$153.45 M+7.33%
December 31, 2024
Summary
- As of February 22, 2025, ALNY TTM revenue is $2.25 billion, with the most recent change of +$153.45 million (+7.33%) on December 31, 2024.
- Over the past year, ALNY TTM revenue has increased by +$419.95 million (+22.97%).
- ALNY TTM revenue is now -4.10% below its all-time high of $2.34 billion, reached on June 30, 2024.
Performance
ALNY TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
ALNY Revenue Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +23.0% | +34.9% | +23.0% |
| 3 y3 years | +166.3% | +34.9% | +23.0% |
| 5 y5 years | +923.1% | +34.9% | +23.0% |
ALNY Revenue Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +166.3% | -21.0% | +178.1% | -4.1% | +166.3% |
| 5 y | 5-year | at high | +923.1% | -21.0% | +727.5% | -4.1% | +923.1% |
| alltime | all time | at high | >+9999.0% | -21.0% | >+9999.0% | -4.1% | >+9999.0% |
Alnylam Pharmaceuticals Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $2.25 B(+23.0%) | $593.17 M(+18.4%) | $2.25 B(+7.3%) |
| Sep 2024 | - | $500.92 M(-24.1%) | $2.09 B(-10.6%) |
| Jun 2024 | - | $659.83 M(+33.5%) | $2.34 B(+17.0%) |
| Mar 2024 | - | $494.33 M(+12.4%) | $2.00 B(+9.6%) |
| Dec 2023 | $1.83 B(+76.2%) | $439.72 M(-41.4%) | $1.83 B(+6.1%) |
| Sep 2023 | - | $750.53 M(+135.5%) | $1.72 B(+39.3%) |
| Jun 2023 | - | $318.75 M(-0.2%) | $1.24 B(+8.2%) |
| Mar 2023 | - | $319.29 M(-4.7%) | $1.14 B(+10.2%) |
| Dec 2022 | $1.04 B(+22.9%) | $335.04 M(+26.8%) | $1.04 B(+8.0%) |
| Sep 2022 | - | $264.31 M(+17.6%) | $960.92 M(+8.7%) |
| Jun 2022 | - | $224.82 M(+5.4%) | $884.25 M(+0.5%) |
| Mar 2022 | - | $213.26 M(-17.5%) | $879.98 M(+4.2%) |
| Dec 2021 | $844.29 M(+71.3%) | $258.54 M(+37.8%) | $844.29 M(+12.7%) |
| Sep 2021 | - | $187.63 M(-14.9%) | $749.31 M(+9.0%) |
| Jun 2021 | - | $220.55 M(+24.2%) | $687.53 M(+20.4%) |
| Mar 2021 | - | $177.57 M(+8.6%) | $570.94 M(+15.8%) |
| Dec 2020 | $492.85 M(+124.3%) | $163.56 M(+30.0%) | $492.85 M(+22.9%) |
| Sep 2020 | - | $125.85 M(+21.1%) | $400.97 M(+16.2%) |
| Jun 2020 | - | $103.96 M(+4.5%) | $345.18 M(+20.7%) |
| Mar 2020 | - | $99.48 M(+38.8%) | $285.93 M(+30.1%) |
| Dec 2019 | $219.75 M(+193.4%) | $71.68 M(+2.3%) | $219.75 M(+30.0%) |
| Sep 2019 | - | $70.06 M(+56.7%) | $169.10 M(+67.2%) |
| Jun 2019 | - | $44.71 M(+34.3%) | $101.11 M(+17.2%) |
| Mar 2019 | - | $33.29 M(+58.3%) | $86.30 M(+15.2%) |
| Dec 2018 | $74.91 M(-16.7%) | $21.03 M(+916.6%) | $74.91 M(-18.4%) |
| Sep 2018 | - | $2.07 M(-93.1%) | $91.80 M(-14.1%) |
| Jun 2018 | - | $29.91 M(+36.6%) | $106.83 M(+15.1%) |
| Mar 2018 | - | $21.90 M(-42.3%) | $92.85 M(+3.3%) |
| Dec 2017 | $89.91 M(+90.7%) | $37.92 M(+121.8%) | $89.91 M(+29.5%) |
| Sep 2017 | - | $17.10 M(+7.3%) | $69.44 M(+5.2%) |
| Jun 2017 | - | $15.93 M(-16.0%) | $66.00 M(+12.3%) |
| Mar 2017 | - | $18.96 M(+8.6%) | $58.77 M(+24.6%) |
| Dec 2016 | $47.16 M(+14.8%) | $17.45 M(+27.9%) | $47.16 M(+26.6%) |
| Sep 2016 | - | $13.65 M(+56.7%) | $37.26 M(+24.5%) |
| Jun 2016 | - | $8.71 M(+18.6%) | $29.93 M(+0.1%) |
| Mar 2016 | - | $7.34 M(-2.7%) | $29.91 M(-27.2%) |
| Dec 2015 | $41.10 M(-18.7%) | $7.55 M(+19.4%) | $41.10 M(-28.6%) |
| Sep 2015 | - | $6.32 M(-27.2%) | $57.56 M(-7.5%) |
| Jun 2015 | - | $8.69 M(-53.1%) | $62.21 M(+2.3%) |
| Mar 2015 | - | $18.54 M(-22.8%) | $60.82 M(+20.3%) |
| Dec 2014 | $50.56 M | $24.02 M(+118.9%) | $50.56 M(+35.2%) |
| Sep 2014 | - | $10.97 M(+50.4%) | $37.39 M(+5.6%) |
| Jun 2014 | - | $7.29 M(-11.8%) | $35.41 M(-3.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2014 | - | $8.28 M(-23.7%) | $36.80 M(-22.0%) |
| Dec 2013 | $47.17 M(-29.3%) | $10.85 M(+20.6%) | $47.17 M(+5.2%) |
| Sep 2013 | - | $8.99 M(+3.5%) | $44.81 M(-14.8%) |
| Jun 2013 | - | $8.69 M(-53.4%) | $52.58 M(-18.8%) |
| Mar 2013 | - | $18.64 M(+119.4%) | $64.78 M(-2.9%) |
| Dec 2012 | $66.72 M(-19.4%) | $8.49 M(-49.3%) | $66.72 M(-15.2%) |
| Sep 2012 | - | $16.76 M(-19.8%) | $78.69 M(-4.9%) |
| Jun 2012 | - | $20.88 M(+1.4%) | $82.72 M(+0.3%) |
| Mar 2012 | - | $20.59 M(+0.6%) | $82.45 M(-0.4%) |
| Dec 2011 | $82.76 M(-17.3%) | $20.45 M(-1.6%) | $82.76 M(-0.9%) |
| Sep 2011 | - | $20.79 M(+0.9%) | $83.49 M(-7.6%) |
| Jun 2011 | - | $20.61 M(-1.4%) | $90.37 M(-6.2%) |
| Mar 2011 | - | $20.90 M(-1.4%) | $96.37 M(-3.7%) |
| Dec 2010 | $100.04 M(-0.5%) | $21.19 M(-23.4%) | $100.04 M(-5.2%) |
| Sep 2010 | - | $27.67 M(+3.9%) | $105.47 M(+3.4%) |
| Jun 2010 | - | $26.62 M(+8.4%) | $102.06 M(+2.0%) |
| Mar 2010 | - | $24.56 M(-7.7%) | $100.04 M(-0.5%) |
| Dec 2009 | $100.53 M(+4.5%) | $26.63 M(+9.8%) | $100.53 M(+2.3%) |
| Sep 2009 | - | $24.25 M(-1.4%) | $98.31 M(-1.5%) |
| Jun 2009 | - | $24.60 M(-1.8%) | $99.80 M(+0.8%) |
| Mar 2009 | - | $25.06 M(+2.7%) | $99.03 M(+3.0%) |
| Dec 2008 | $96.16 M(+88.9%) | $24.40 M(-5.2%) | $96.16 M(+6.9%) |
| Sep 2008 | - | $25.73 M(+8.0%) | $89.99 M(+11.7%) |
| Jun 2008 | - | $23.83 M(+7.4%) | $80.57 M(+22.3%) |
| Mar 2008 | - | $22.19 M(+21.7%) | $65.87 M(+29.4%) |
| Dec 2007 | $50.90 M(+89.0%) | $18.23 M(+11.7%) | $50.90 M(+28.4%) |
| Sep 2007 | - | $16.32 M(+78.6%) | $39.65 M(+25.7%) |
| Jun 2007 | - | $9.13 M(+26.5%) | $31.54 M(+10.9%) |
| Mar 2007 | - | $7.22 M(+3.4%) | $28.43 M(+5.6%) |
| Dec 2006 | $26.93 M(+371.1%) | $6.98 M(-15.0%) | $26.93 M(+25.2%) |
| Sep 2006 | - | $8.21 M(+36.4%) | $21.50 M(+46.2%) |
| Jun 2006 | - | $6.02 M(+5.3%) | $14.70 M(+50.2%) |
| Mar 2006 | - | $5.72 M(+268.4%) | $9.79 M(+71.3%) |
| Dec 2005 | $5.72 M(+33.6%) | $1.55 M(+9.8%) | $5.72 M(-16.1%) |
| Sep 2005 | - | $1.41 M(+27.5%) | $6.81 M(+0.7%) |
| Jun 2005 | - | $1.11 M(-32.6%) | $6.76 M(+16.9%) |
| Mar 2005 | - | $1.64 M(-37.9%) | $5.79 M(+35.3%) |
| Dec 2004 | $4.28 M(+2330.7%) | $2.65 M(+93.6%) | $4.28 M(+155.3%) |
| Sep 2004 | - | $1.37 M(+943.5%) | $1.68 M(+374.8%) |
| Jun 2004 | - | $131.00 K(-2.2%) | $353.00 K(+59.0%) |
| Mar 2004 | - | $134.00 K(+204.5%) | $222.00 K(+152.3%) |
| Dec 2003 | $176.00 K | $44.00 K(0.0%) | $88.00 K(+100.0%) |
| Sep 2003 | - | $44.00 K | $44.00 K |
FAQ
- What is Alnylam Pharmaceuticals annual revenue?
- What is the all time high annual revenue for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual revenue year-on-year change?
- What is Alnylam Pharmaceuticals quarterly revenue?
- What is the all time high quarterly revenue for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly revenue year-on-year change?
- What is Alnylam Pharmaceuticals TTM revenue?
- What is the all time high TTM revenue for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals TTM revenue year-on-year change?
What is Alnylam Pharmaceuticals annual revenue?
The current annual revenue of ALNY is $2.25 B
What is the all time high annual revenue for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual revenue is $2.25 B
What is Alnylam Pharmaceuticals annual revenue year-on-year change?
Over the past year, ALNY annual revenue has changed by +$419.95 M (+22.97%)
What is Alnylam Pharmaceuticals quarterly revenue?
The current quarterly revenue of ALNY is $593.17 M
What is the all time high quarterly revenue for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly revenue is $750.53 M
What is Alnylam Pharmaceuticals quarterly revenue year-on-year change?
Over the past year, ALNY quarterly revenue has changed by +$153.45 M (+34.90%)
What is Alnylam Pharmaceuticals TTM revenue?
The current TTM revenue of ALNY is $2.25 B
What is the all time high TTM revenue for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high TTM revenue is $2.34 B
What is Alnylam Pharmaceuticals TTM revenue year-on-year change?
Over the past year, ALNY TTM revenue has changed by +$419.95 M (+22.97%)